Chiron’s European Flu Vaccine Dose Expectations Cut By 8 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
Only 4 mil. doses of Chiron's Begrivac flu vaccine are expected to be supplied to non-U.S. markets after quality assurance concerns at Chiron’s Marburg, Germany facility leads the company to reduce supply expectations. FDA is beginning to inspect Liverpool plant, where manufacturing problems limited Fluvirin supply for 2004/2005.